In this retrospective, single-center, case series, we show that combining the multi-kinase inhibitor regorafenib with standard-of-care BRAF/MEK inhibitors can have meaningful anti-tumor activity in melanoma patients with progressive MBM with an acceptable safety profile. This evidence concerns the gene MAP2K7 and neoplasm.